Venture Life Group PLC Notice of Results Update (3683T)
20 Marzo 2019 - 8:02AM
UK Regulatory
TIDMVLG
RNS Number : 3683T
Venture Life Group PLC
20 March 2019
20 March 2019
VENTURE LIFE GROUP PLC
("Venture Life" or the "Group")
Notice of Results Update
Venture Life Group plc (AIM: VLG), announces that the Company
expects to announce its audited results for the year ended 31
December 2018 in early April or before. This minor delay to the
original timetable is a result of the audit process taking slightly
longer than planned, due principally to recent personnel changes in
the Company's finance function and increased complexity arising
from the implications of reporting standards, including IFRS 9 and
15. Further to the announcement on 29 January 2019, the Company
continues to expect to report revenue of GBP18.7 million, a 16%
increase over the prior year and for adjusted EBITDA to be at least
in line with market expectations.
ENDS
For further information, please contact:
+44(0) 1344
Venture Life Group PLC 578004
Jerry Randall, Chief Executive Officer
+44(0)20 7397
Cenkos Securities Ltd (Nomad and Broker) 8900
Mark Connelly / Stephen Keys / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Alma PR
Rebecca Sanders-Hewett / Hilary Buchanan / Helena +44(0)20 3405
Bogle / Jessica Joynson 0208
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for maintaining brain function, medical devices for
women's intimate healthcare and proctology and dermo-cosmetics for
addressing the signs of ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORCKCDQKBKBKND
(END) Dow Jones Newswires
March 20, 2019 03:02 ET (07:02 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024